Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302732 | 0.90 | TSHR (0.67) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL10111043 | 0.89 | TSHR (0.57) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL15871994 | 0.89 | TSHR (0.65) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL5929495 | 0.87 | TSHR (0.67) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL9596753 | 0.86 | L3MBTL1 (0.51) | TSHRTDP1CYP2C9SMN1; SMN2CYP1A2 | |
| SCHEMBL5266458 | 0.85 | TSHR (0.70) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL7056362 | 0.84 | L3MBTL1 (0.55) | TSHRSMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL17124807 | 0.84 | TSHR (0.59) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL2092305 | 0.83 | TSHR (0.58) | TSHRTDP1CYP2C9SMN1; SMN2PPARA | |
| SCHEMBL172302 | 0.82 | TSHR (0.61) | TSHRTDP1CYP2C9SMN1; SMN2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108546245-A | A kind of preparation method of antiproliferative activity intermediate ML-098 | 绍兴文理学院 | 2018-09-18 | — | — | CN | claimed |
| CN-111465589-B | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-11538992-B2 | Formulation of an organic functional material | MERCK PATENT GMBH (DE) | 2022-12-27 | — | — | US | disclosed |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | TEIJIN LIMITED (JP) | 2022-05-24 | — | — | US | disclosed |
| EP-3747856-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | Teijin Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | TEIJIN LIMITED (JP) | 2020-11-12 | — | — | US | disclosed |
| CN-111465589-A | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2020-07-28 | — | — | CN | disclosed |
| WO-2020085222-A1 | CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME | 帝人株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20200127203-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2019151264-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | 帝人株式会社 | 2019-08-08 | — | — | WO | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-0391942-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4935540-A | OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING | EASTMAN CHEMICAL COMPANY | 1990-06-19 | — | — | US | disclosed |
| WO-1989003378-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4804777-A | OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST | EASTMAN KODAK COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0011793-B1 | PROCESS FOR PREPARING ARYLOXYACETIC ACIDS | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| US-4238625-A | ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
| EP-0011793-A1 | Process for preparing aryloxyacetic acids | BAYER AG (DE) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | RFT1, AFF1, RER1 | TSHR 2403/4885TDP1 3407/4885CYP2C9 2841/4885 |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | RFT1, AFF1, RER1 | TSHR 2403/4885TDP1 3407/4885CYP2C9 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.